8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Mar 17, 2026·SEC
Material company update
Mar 13, 2026·SEC
Indivior Pharmaceuticals Inc(INDV)Earnings, Financials & Key Ratios
INDV•NASDAQ
23.4× P/E·Price updated Jun 19, 2026
AboutIndivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Show more
- Revenue$1.24B+4.3%
- EBITDA$285M+367.2%
- Net Income$210M+10400.0%
- EPS (Diluted)1.64+10833.3%
- Gross Margin80.15%-0.5%
- EBITDA Margin23%+348.0%
- Operating Margin21.39%+694.0%
- Net Margin16.95%+9964.8%
INDV Key Insights
Indivior Pharmaceuticals Inc (INDV) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 82 (top 18%)
- ✓Strong 5Y sales CAGR of 13.9%
- ✓Share count reduced 3.8% through buybacks
- ✓Efficient asset utilization: 1.0x turnover
✗Weaknesses
- ✗Negative free cash flow
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when INDV posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
INDV Price & Volume
Indivior Pharmaceuticals Inc (INDV) stock price & volume — 10-year historical chart
Loading chart...
INDV Growth Metrics
Indivior Pharmaceuticals Inc (INDV) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years13.88%
3 Years11.2%
TTM10.25%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM1830.77%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM1314.29%
Return on Capital
10 Years42.56%
5 Years14.77%
3 Years20.4%
Last Year79.1%
INDV Recent Earnings
Indivior Pharmaceuticals Inc (INDV) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
Apr 30, 2026Metric
Actual
Est
EPS
$0.96+50.0%
$0.64
Rev
$317M+16.2%
$273M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.82+26.2%
$0.65
Rev
$358M+17.1%
$306M
Q4 2025
Oct 30, 2025Metric
Actual
Est
EPS
$0.72+89.5%
$0.38
Rev
$314M+2.5%
$306M
Q3 2025
Jul 31, 2025Metric
Actual
Est
EPS
$0.51+96.2%
$0.26
Rev
$302M+18.3%
$255M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $0.96vs $0.64+50.0% | $317Mvs $273M+16.2% |
| Q1 2026 | Feb 26, 2026 | $0.82vs $0.65+26.2% | $358Mvs $306M+17.1% |
| Q4 2025 | Oct 30, 2025 | $0.72vs $0.38+89.5% | $314Mvs $306M+2.5% |
| Q3 2025 | Jul 31, 2025 | $0.51vs $0.26+96.2% | $302Mvs $255M+18.3% |
Based on last 12 quarters of dataView full earnings history →
INDV Peer Comparison
Indivior Pharmaceuticals Inc (INDV) competitors in Therapy-focused branded biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RBBN | 449.55M | 2.56 | 11.64 | 1.28% | 3.8% | 7.85% | 0.90 | |
 AVPT | 2.21B | 10.41 | 69.40 | 26.93% | 10.51% | 10.2% | 0.02 | |
 BHVN | 1.44B | 13.57 | -1.98 | -8.66% | 5.36 | |||
 ALKS | 7.5B | 44.99 | 31.46 | -5.25% | 9.78% | 8.82% | 0.04 | |
 BHC | 1.78B | 4.77 | 11.09 | 8.53% | -11.27% | 5.88% | 56.36 | |
 SUPN | 2.56B | 44.38 | -65.26 | 8.63% | -3.74% | -2.73% | 0.04 | |
 COLL | 1.09B | 33.54 | 19.39 | 23.62% | 9.41% | 26.74% | 3.12 | |
 MTLS | 396.34M | 6.71 | 44.84 | -3.63% | 3.72% | 4.11% | 0.26 |
Compare INDV vs Peers
Indivior Pharmaceuticals Inc (INDV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
INDV Income Statement
Indivior Pharmaceuticals Inc (INDV) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 1.15B | 959.92M | 785M | 647M | 791M | 901M | 1.09B | 1.19B | 1.24B | 1.29B |
Revenue Growth % | 18.5% | -16.39% | -18.22% | -17.58% | 22.26% | 13.91% | 21.31% | 8.69% | 4.29% | 10.25% |
Cost of Goods Sold | 122.9M | 134.68M | 140M | 97M | 127M | 151M | 174M | 231M | 246M | 218M |
COGS % of Revenue | 10.7% | 14.03% | 17.83% | 14.99% | 16.06% | 16.76% | 15.92% | 19.44% | 19.85% | - |
Gross Profit | 1.03B▲ 0% | 825.25M▼ 19.5% | 645M▼ 21.8% | 550M▼ 14.7% | 664M▲ 20.7% | 750M▲ 13.0% | 919M▲ 22.5% | 957M▲ 4.1% | 993M▲ 3.8% | 1.07B▲ 0% |
Gross Margin % | 89.3% | 85.97% | 82.17% | 85.01% | 83.94% | 83.24% | 84.08% | 80.56% | 80.15% | 83.11% |
Gross Profit Growth % | 19.48% | -19.5% | -21.84% | -14.73% | 20.73% | 12.95% | 22.53% | 4.13% | 3.76% | - |
Operating Expenses | 601.89M | 508.14M | 467M | 706M | 451M | 831M | 1.07B | 925M | 728M | 643M |
OpEx % of Revenue | 52.42% | 52.94% | 59.49% | 109.12% | 57.02% | 92.23% | 98.35% | 77.86% | 58.76% | - |
Selling, General & Admin | 508.4M | 444.14M | 395M | 649M | 431M | 469M | 569M | 618M | 634M | 570M |
SG&A % of Revenue | 44.28% | 46.27% | 50.32% | 100.31% | 54.49% | 52.05% | 52.06% | 52.02% | 51.17% | - |
Research & Development | 93.49M | 63.99M | 53M | 40M | 52M | 74M | 116M | 107M | 97M | 74M |
R&D % of Revenue | 8.14% | 6.67% | 6.75% | 6.18% | 6.57% | 8.21% | 10.61% | 9.01% | 7.83% | - |
Other Operating Expenses | 0 | 0 | 19M | 17M | -32M | 288M | 390M | 200M | -3M | -1000K |
Operating Income | 423.32M▲ 0% | 317.11M▼ 25.1% | 178M▼ 43.9% | -156M▼ 187.6% | 213M▲ 236.5% | -81M▼ 138.0% | -156M▼ 92.6% | 32M▲ 120.5% | 265M▲ 728.1% | 430M▲ 0% |
Operating Margin % | 36.87% | 33.03% | 22.68% | -24.11% | 26.93% | -8.99% | -14.27% | 2.69% | 21.39% | 33.31% |
Operating Income Growth % | 25.27% | -25.09% | -43.87% | -187.64% | 236.54% | -138.03% | -92.59% | 120.51% | 728.13% | - |
EBITDA | 436.97M | 332.39M | 206M | -130M | 235M | -65M | -141M | 61M | 285M | 447M |
EBITDA Margin % | 38.06% | 34.63% | 26.24% | -20.09% | 29.71% | -7.21% | -12.9% | 5.13% | 23% | 34.62% |
EBITDA Growth % | 24.59% | -23.93% | -38.02% | -163.11% | 280.77% | -127.66% | -116.92% | 143.26% | 367.21% | 480.52% |
D&A (Non-Cash Add-back) | 13.66M | 15.28M | 28M | 26M | 22M | 16M | 15M | 29M | 20M | 17M |
EBIT | 193M | 295.14M | 202M | -149M | 216M | -62M | -114M | 55M | 284M | 435M |
Net Interest Income | -42M | -14M | 2M | -17M | -22M | -10M | 8M | -18M | -23M | -19M |
Interest Income | 7M | 17M | 24M | 7M | 4M | 19M | 43M | 23M | 22M | 21M |
Interest Expense | 49M | 31M | 22M | 24M | 26M | 29M | 35M | 41M | 45M | 40M |
Other Income/Expense | -56M | -14M | 2M | -17M | -23M | -8M | 7M | -18M | -26M | -135M |
Pretax Income | 143.91M▲ 0% | 265.53M▲ 84.5% | 180M▼ 32.2% | -173M▼ 196.1% | 190M▲ 209.8% | -89M▼ 146.8% | -149M▼ 67.4% | 14M▲ 109.4% | 239M▲ 1607.1% | 295M▲ 0% |
Pretax Margin % | 12.53% | 27.66% | 22.93% | -26.74% | 24.02% | -9.88% | -13.63% | 1.18% | 19.29% | 22.85% |
Income Tax | 82.98M | 2.87M | 46M | -25M | -15M | -44M | -20M | 11M | 29M | 44M |
Effective Tax Rate % | 57.66% | 1.08% | 25.56% | 14.45% | -7.89% | 49.44% | 13.42% | 78.57% | 12.13% | 14.92% |
Net Income | 60.92M▲ 0% | 262.67M▲ 331.1% | 134M▼ 49.0% | -148M▼ 210.4% | 205M▲ 238.5% | -44M▼ 121.5% | -129M▼ 193.2% | 2M▲ 101.6% | 210M▲ 10400.0% | 251M▲ 0% |
Net Margin % | 5.31% | 27.36% | 17.07% | -22.87% | 25.92% | -4.88% | -11.8% | 0.17% | 16.95% | 19.44% |
Net Income Growth % | 90.08% | 331.14% | -48.98% | -210.45% | 238.51% | -121.46% | -193.18% | 101.55% | 10400% | 1830.77% |
Net Income (Continuing) | 60.92M | 262.67M | 134M | -148M | 205M | -45M | -129M | 3M | 210M | 251M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 0.41▲ 0% | 1.75▲ 326.8% | 0.92▼ 47.4% | -1.08▼ 217.4% | 1.31▲ 221.3% | -0.37▼ 128.2% | 0.01▲ 103.8% | 0.02▲ 6.4% | 1.64▲ 10833.3% | 1.95▲ 0% |
EPS Growth % | 86.36% | 326.83% | -47.43% | -217.39% | 221.3% | -128.24% | 103.81% | 6.38% | 10833.33% | 1314.29% |
EPS (Basic) | 0.42 | 1.81 | 0.95 | -1.08 | 1.38 | -0.37 | 0.01 | 0.02 | 1.68 | - |
Diluted Shares Outstanding | 149.7M | 150.23M | 151.07M | 146.57M | 154.23M | 139.01M | 141.8M | 133M | 128M | 129M |
Basic Shares Outstanding | 144.23M | 145.43M | 146.05M | 146.57M | 145.66M | 139.01M | 137.31M | 132M | 125M | 125.35M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
INDV Balance Sheet
Indivior Pharmaceuticals Inc (INDV) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 1.22B | 1.33B | 1.36B | 1.19B | 1.44B | 1.27B | 1.27B | 839M | 652M | 667M |
Cash & Short-Term Investments | 863M | 924M | 1.06B | 858M | 1.1B | 897.83M | 410M | 320M | 195M | 175M |
Cash Only | 863M | 924M | 1.06B | 858M | 1.1B | 778.18M | 316M | 319M | 195M | 175M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 119.64M | 94M | 1M | 0 | 0 |
Accounts Receivable | 257M | 278M | 204M | 219M | 202M | 220M | 254M | 254M | 255M | 285M |
Days Sales Outstanding | 81.7 | 105.71 | 94.85 | 123.55 | 93.21 | 89.12 | 84.82 | 78.04 | 75.12 | 74.36 |
Inventory | 52M | 78M | 73M | 93M | 95M | 114.62M | 135M | 178M | 153M | 152M |
Days Inventory Outstanding | 154.44 | 211.4 | 190.32 | 349.95 | 273.03 | 277.05 | 283.19 | 281.26 | 227.01 | 255.75 |
Other Current Assets | 38M | 49M | 0 | 0 | 27M | 18M | 444M | 87M | 15M | 55M |
Total Non-Current Assets | 219M | 218M | 292M | 344M | 388M | 512.76M | 499M | 481M | 552M | 530M |
Property, Plant & Equipment | 54M | 57M | 107M | 103M | 95M | 85.46M | 124M | 139M | 170M | 179M |
Fixed Asset Turnover | 21.26x | 16.84x | 7.34x | 6.28x | 8.33x | 10.54x | 8.81x | 8.55x | 7.29x | 7.88x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2M | 0 | 2M |
Intangible Assets | 0 | 0 | 72M | 62M | 82M | 70M | 13M | 5M | 2M | 0 |
Long-Term Investments | 15M | 33M | 0 | 0 | 0 | 98.53M | 41M | 26M | 28M | 110M |
Other Non-Current Assets | 92M | 84M | 73M | 104M | 106M | 38.58M | 28M | 29M | 26M | 26M |
Total Assets | 1.44B▲ 0% | 1.55B▲ 7.1% | 1.65B▲ 6.8% | 1.53B▼ 7.3% | 1.83B▲ 19.7% | 1.78B▼ 2.9% | 1.76B▼ 0.8% | 1.32B▼ 25.3% | 1.2B▼ 8.7% | 1.2B▲ 0% |
Asset Turnover | 0.80x | 0.62x | 0.48x | 0.42x | 0.43x | 0.51x | 0.62x | 0.90x | 1.03x | 0.98x |
Asset Growth % | 19.44% | 7.13% | 6.79% | -7.32% | 19.66% | -2.92% | -0.76% | -25.27% | -8.72% | -30.37% |
Total Current Liabilities | 854M | 818M | 742M | 599M | 804M | 1.02B | 1.29B | 939M | 914M | 779M |
Accounts Payable | 40M | 47M | 499M | 416M | 26M | 33M | 39M | 63M | 48M | 0 |
Days Payables Outstanding | 118.8 | 127.38 | 1.3K | 1.57K | 74.72 | 79.77 | 81.81 | 99.55 | 71.22 | 58.18 |
Short-Term Debt | 5M | 4M | 9M | 12M | 3M | 3M | 12M | 18M | 39M | 9M |
Deferred Revenue (Current) | 41M | 24M | 0 | 0 | 0 | 9.05M | 0 | 0 | 0 | 0 |
Other Current Liabilities | 617M | 603M | 195M | 156M | 635M | 391M | 1.16B | 802M | 722M | 770M |
Current Ratio | 1.43x | 1.62x | 1.83x | 1.98x | 1.80x | 1.24x | 0.98x | 0.89x | 0.71x | 0.86x |
Quick Ratio | 1.37x | 1.53x | 1.73x | 1.83x | 1.68x | 1.12x | 0.88x | 0.70x | 0.55x | 0.66x |
Cash Conversion Cycle | 117.34 | 189.72 | -1.02K | -1.09K | 291.52 | 286.41 | 286.2 | 259.75 | 230.91 | 271.93 |
Total Non-Current Liabilities | 793M | 663M | 701M | 850M | 825M | 702.78M | 666M | 728M | 388M | 562M |
Long-Term Debt | 477M | 237M | 233M | 230M | 239M | 237M | 237M | 315M | 290M | 14M |
Capital Lease Obligations | 0 | 0 | 51M | 43M | 36M | 29M | 34M | 32M | 22M | 75M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 5M | 0 | 3M | 3M |
Other Non-Current Liabilities | 316M | 426M | 417M | 577M | 550M | 436.78M | 390M | 381M | 73M | 548M |
Total Liabilities | 1.65B | 1.48B | 1.44B | 1.45B | 1.63B | 1.73B | 1.96B | 1.67B | 1.3B | 1.34B |
Total Debt | 482M | 241M | 293M | 285M | 286M | 277M | 283M | 375M | 351M | 23M |
Net Debt | -381M | -683M | -767M | -573M | -816M | -501.18M | -33M | 56M | 156M | -152M |
Debt / Equity | - | 3.65x | 1.40x | 3.48x | 1.41x | 5.40x | - | - | - | -0.16x |
Debt / EBITDA | 1.10x | 0.73x | 1.42x | - | 1.22x | - | - | 6.15x | 1.23x | 0.05x |
Net Debt / EBITDA | -0.87x | -2.05x | -3.72x | - | -3.47x | - | - | 0.92x | 0.55x | -0.34x |
Interest Coverage | 3.94x | 9.52x | 9.18x | -6.21x | 8.31x | -2.14x | -3.26x | 1.34x | 6.31x | 10.88x |
Total Equity | -203M▲ 0% | 66M▲ 132.5% | 209M▲ 216.7% | 82M▼ 60.8% | 203M▲ 147.6% | 51.28M▼ 74.7% | -191M▼ 472.5% | -348M▼ 82.2% | -98M▲ 71.8% | -144M▲ 0% |
Equity Growth % | 31.19% | 132.51% | 216.67% | -60.77% | 147.56% | -74.74% | -472.5% | -82.2% | 71.84% | -15.65% |
Book Value per Share | -1.36 | 0.44 | 1.38 | 0.56 | 1.32 | 0.37 | -1.35 | -2.62 | -0.77 | -1.12 |
Total Shareholders' Equity | -203M | 66M | 209M | 82M | 203M | 51.28M | -191M | -348M | -98M | -144M |
Common Stock | 72M | 73M | 73M | 73M | 70M | 68.37M | 68M | 62M | 62M | 0 |
Retained Earnings | 1.03B | 1.31B | 1.45B | 1.31B | 1.44B | 1.31B | -295M | -454M | -243M | -280M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -1.31B | -1.33B | -1.32B | -1.31B | 0 | -1.34B | -1.35B | -46M | -30M | -29M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
INDV Cash Flow Statement
Indivior Pharmaceuticals Inc (INDV) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 309.87M | 289.41M | 151M | -193M | 353M | -4M | -300M | 36M | -27M | -102.96M |
Operating CF Margin % | 26.99% | 30.15% | 19.24% | -29.83% | 44.63% | -0.44% | -27.45% | 3.03% | -2.18% | - |
Operating CF Growth % | -16.86% | -6.6% | -47.82% | -227.81% | 282.9% | -101.13% | -7400% | 112% | -175% | -4423.79% |
Net Income | 60.92M | 262.67M | 178M | -156M | 213M | -44M | -129M | 2M | 210M | 251M |
Depreciation & Amortization | 13.66M | 15.28M | 28M | 26M | 22M | 16M | 15M | 29M | 20M | 19M |
Stock-Based Compensation | 0 | 0 | 3M | 8M | 11M | 16M | 21M | 24M | 26M | 29M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6M | -46M | -24M |
Other Non-Cash Items | 177.52M | 20.06M | 21M | -52M | -66M | -110M | 87M | 16M | 20M | -104.9M |
Working Capital Changes | 148.11M | 27.7M | -79M | -19M | 173M | 118M | -294M | -41M | -257M | -273.27M |
Change in Receivables | -61.97M | -31.52M | 79M | 15M | -25M | -21M | -33M | -1M | 3M | -7.44M |
Change in Inventory | -6.3M | -29.61M | 7M | -16M | -3M | -30M | -15M | -45M | 18M | 13.4M |
Change in Payables | 5.25M | 55.4M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Investing | -45.17M | -3.82M | -2M | -4M | -14M | -222M | -95M | 69M | -66M | -81.69M |
Capital Expenditures | -45.17M | -39.16M | -7M | -4M | -4M | -5M | -8M | -29M | -66M | -82.69M |
CapEx % of Revenue | 3.93% | 4.08% | 0.89% | 0.62% | 0.51% | 0.55% | 0.73% | 2.44% | 5.33% | 6.41% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | -129M | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 35.34M | 5M | 0 | -10M | 1M | -42M | -2M | 20M | 7M |
Cash from Financing | -88.23M | -226.37M | -13M | -10M | -94M | -101M | -64M | -102M | -30M | -5.63M |
Debt Issued (Net) | -86M | -229.24M | -4M | -4M | 14M | -3M | -12M | 92M | -17M | -13.08M |
Equity Issued (Net) | 2M | 3M | 0 | 1M | -100M | -88M | -30M | -170M | -9M | 1.86M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | -101M | -90M | -33M | -173M | -11M | -126.14M |
Other Financing | 0 | -10.76M | -9M | -7M | -8M | -10M | -22M | -24M | -4M | 5.59M |
Net Change in Cash | 171M▲ 0% | 61M▼ 64.3% | 136M▲ 123.0% | -202M▼ 248.5% | 244M▲ 220.8% | -328M▼ 234.4% | -458M▼ 39.6% | 3M▲ 100.7% | -124M▼ 4233.3% | -197M▲ 0% |
Free Cash Flow | 264.7M▲ 0% | 250.25M▼ 5.5% | 144M▼ 42.5% | -197M▼ 236.8% | 319M▲ 261.9% | -9M▼ 102.8% | -353M▼ 3822.2% | 7M▲ 102.0% | -93M▼ 1428.6% | -184.62M▲ 0% |
FCF Margin % | 23.06% | 26.07% | 18.34% | -30.45% | 40.33% | -1% | -32.3% | 0.59% | -7.51% | -14.3% |
FCF Growth % | -22.3% | -5.46% | -42.46% | -236.81% | 261.93% | -102.82% | -3822.22% | 101.98% | -1428.57% | -240.57% |
FCF per Share | 1.77 | 1.67 | 0.95 | -1.34 | 2.07 | -0.06 | -2.49 | 0.05 | -0.73 | -1.43 |
FCF Conversion (FCF/Net Income) | 5.09x | 1.10x | 1.13x | 1.30x | 1.72x | 0.09x | 2.33x | 18.00x | -0.13x | -0.74x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
INDV Key Ratios
Indivior Pharmaceuticals Inc (INDV) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | 397.98% | 97.45% | -101.72% | 143.86% | -34.61% | - | - | - | -142.01% |
Return on Invested Capital (ROIC) | - | - | - | - | - | - | - | - | 342.67% | -137.82% |
Gross Margin | 89.3% | 85.97% | 82.17% | 85.01% | 83.94% | 83.24% | 84.08% | 80.56% | 80.15% | 83.11% |
Net Margin | 5.31% | 27.36% | 17.07% | -22.87% | 25.92% | -4.88% | -11.8% | 0.17% | 16.95% | 19.44% |
Debt / Equity | - | 3.65x | 1.40x | 3.48x | 1.41x | 5.40x | - | - | - | -0.16x |
Interest Coverage | 3.94x | 9.52x | 9.18x | -6.21x | 8.31x | -2.14x | -3.26x | 1.34x | 6.31x | 10.88x |
FCF Conversion | 5.09x | 1.10x | 1.13x | 1.30x | 1.72x | 0.09x | 2.33x | 18.00x | -0.13x | -0.74x |
Revenue Growth | 18.5% | -16.39% | -18.22% | -17.58% | 22.26% | 13.91% | 21.31% | 8.69% | 4.29% | 10.25% |
Related:INDV Dividend History·INDV Revenue History·INDV Price History·INDV P/E History·INDV Financial Ratios·INDV Institutional Holders
INDV SEC Filings & Documents
Indivior Pharmaceuticals Inc (INDV) SEC filings — annual & quarterly reports (10-K, 10-Q)
INDV Frequently Asked Questions
Indivior Pharmaceuticals Inc (INDV) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Indivior Pharmaceuticals Inc (INDV) reported $1.29B in revenue for fiscal year 2025. This represents a 33% increase from $968.9M in 2016.
Indivior Pharmaceuticals Inc (INDV) grew revenue by 4.3% over the past year. Growth has been modest.
Yes, Indivior Pharmaceuticals Inc (INDV) is profitable, generating $251.0M in net income for fiscal year 2025 (16.9% net margin).
Dividend & Returns
Indivior Pharmaceuticals Inc (INDV) had negative free cash flow of $184.6M in fiscal year 2025, likely due to heavy capital investments.